Effect of Loratadine in Lymphangioleiomyomatosis

NCT05190627 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Lymphangioleiomyomatosis

Interventions

DRUG: Loratadine
DRUG: Placebo 10mg/day added to rapamycin for 12 months

Sponsor

Institut d'Investigació Biomèdica de Bellvitge